Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis-Reference-Cited by-同舟云学术

Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis

Published:2014-04 Issue:4 Volume:28 Page:168-175
ISSN:1087-2914
Container-title:AIDS Patient Care and STDs
language:en
Short-container-title:AIDS Patient Care and STDs

Author:

Behrens Georg¹,Rijnders Bart²,Nelson Mark³,Orkin Chloe⁴,Cohen Calvin⁵,Mills Anthony⁶,Elion Richard A.⁷,Vanveggel Simon⁸,Stevens Marita⁸,Rimsky Laurence⁸,Thorpe David⁹,Bosse Matthew⁹,White Kirsten¹⁰,Zhong Lijie¹⁰,DeMorin Jennifer¹⁰,Chuck Susan K.¹⁰

Affiliation:

1. Hanover Medical School, Hanover, Germany.

2. Erasmus Medisch Centrum, Rotterdam, Netherlands.

3. Chelsea and Westminster Hospital, London, United Kingdom.

4. Barts and The London HIV Service, London, United Kingdom.

5. Community Research Initiative of New England, Boston, Massachusetts.

6. Anthony Mills MD Inc, Los Angeles, Los Angeles, California.

7. Whitman-Walker Clinic, Washington, District of Columbia.

8. Janssen Infectious Diseases BVBA, Beerse, Belgium.

9. Gilead Sciences, Europe Limited, Stockley Park, United Kingdom.

10. Gilead Sciences Inc, Foster City, California.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Link

http://www.liebertpub.com/doi/pdf/10.1089/apc.2013.0310

Reference18 articles.

1. SUSTIVA® (efavirenz) capsules and tablets for oral use. US Prescribing Information. Bristol-Myers Squibb Company. Princeton, NJ, May 2013.

2. Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100 000 copies/ml or less

3. Eviplera 200 mg/25mg/245mg film-coated tablets: Summary of Product Characteristics. Gilead Sciences International Limited. Cambridge, UK, December 2013.

4. COMPLERA® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) tablets, for oral use. US Prescribing Information. Gilead Sciences, Inc. Foster City, CA. Revised June 2013.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hidden cues for approach and avoidance motivation: implicit cognitive associations among patients with Nonadherence to HIV treatment;AIDS Care;2021-12-01

2. Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis;Frontiers in Pharmacology;2021-07-21

3. The Occurrence of rtA194T Mutant After Long-Term Lamivudine Monotherapy Remains Sensitive to Tenofovir Disoproxil Fumarate: A Case Report;Infection and Drug Resistance;2021-03

4. Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update;Southern African Journal of HIV Medicine;2020-09-16

5. Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV;Pharmaceuticals;2020-06-11